natgillin/translations-raw huggingface dataset:
Sevelamer carbonate Zentiva is not absorbed and may affect the bioavailability of other medicinal products.
Sevelamer carbonate Zentiva se ne apsorbira i može utjecati na bioraspoloživost drugih lijekova.
Sevelamer carbonate Zentiva is not absorbed compound and may affect the bioavailability of other medicinal products.
Sevelamer carbonate Zentiva se ne apsorbira i može utjecati na bioraspoloživost drugih lijekova.
Sevelamer carbonate Zentiva is not indicated for the control of hyperparathyroidism.
Sevelamer carbonate Zentiva nije indiciran za kontrolu hiperparatireoze.
Sevelamer carbonate Zentiva is unlikely to affect your ability to drive or to use machines.
Nije vjerojatno da će Sevelamer carbonate Zentiva utjecati na sposobnost upravljanja vozilima i strojevima.
Sevelamer carbonate Zentiva is used to control hyperphosphataemia (high blood phosphate levels) in: adult patients on dialysis (a blood clearance technique).
Sevelamer carbonate Zentiva se koristi za kontorolu hiperfosfatemije (visoka razina fosfata u krvi) u: odraslih bolesnika na dijalizi (tehnika pročišćavanja krvi).
Sevelamer carbonate Zentiva must be taken three times a day with meals and patients should keep to their prescribed diets.
Sevelamer carbonate Zentiva mora se uzimati tri puta na dan uz obroke, a bolesnici se trebaju pridržavati svojeg propisanog plana prehrane.
Sevelamer carbonate Zentiva must be taken three times per day with meals.
Sevelamer carbonate Zentiva se mora uzimati triput na dan uz obrok.
Sevelamer carbonate Zentiva must not be used in people with hypophosphataemia (low blood phosphate levels) or with bowel obstruction (a blockage in the gut).
Sevelamer carbonate Zentiva ne smije se koristiti u osoba s hipofosfatemijom (niskim koncentracijama fosfata u krvi) ili s obstrukcijom crijeva (blokadom u crijevima).
Sevelamer carbonate Zentiva powder for oral suspension is a pale yellow powder supplied in a foil sachet with a heat seal.
Sevelamer carbonate Zentiva prašak za oralnu suspenziju je blijedožuti prašak koji se nalazi u toplinski zalijepljenoj vrećici od folije.
Sevelamer carbonate Zentiva powder for oral suspension must be taken three times per day with meals.
Sevelamer carbonate Zentiva prašak za oralnu suspenziju mora se uzimati triput na dan uz obrok.
Sevelamer carbonate Zentiva sevelamer carbonate
Sevelamer carbonate Zentiva sevelamerkarbonat
Sevelamer carbonate Zentiva should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Sevelamer carbonate Zentiva se treba koristiti zajedno s ostalim metodama liječenja poput nadomjestaka kalcija i primjene vitamina D, kako bi se spriječio razvoj bolesti kostiju.
Sevelamer carbonate Zentiva should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Sevelamer carbonate Zentiva treba koristiti s drugim terapijama poput dodataka kalcija i vitamina D kako bi se spriječio razvoj koštanih bolesti.
Sevelamer carbonate Zentiva should be used with other treatments such as calcium supplements and vitamin D to prevent the development of bone disease.
Sevelamer carbonate Zentiva treba koristiti zajedno s ostalim metodama liječenja poput nadomjestaka kalcija i primjene vitamina D, kako bi se spriječio razvoj bolesti kostiju.
Sevelamer carbonate Zentiva should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Sevelamer carbonate Zentiva se treba primjenjivati u sklopu multiterapijskog pristupa, koji može uključivati nadomjestke kalcija i 1,25-dihidroksi vitamin D3 ili neki od njegovih analoga, kako bi se kontrolirao razvoj bubrežne osteodistrofije.
Sevelamer carbonate Zentiva should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease.
Sevelamer carbonate Zentiva treba primjenjivati u sklopu multiterapijskog pristupa, koji može uključivati nadomjestke kalcija i 1,25-dihidroksi vitamin D3 ili neki od njegovih analoga, kako bi se kontrolirao razvoj bubrežne osteodistrofije.
Sevelamer carbonate Zentiva should not be taken at the same time as ciprofloxacin (an antibiotic).
Sevelamer carbonate Zentiva se ne bi smio uzimati istodobno s ciprofloksacinom (antibiotik).
Sevelamer carbonate Zentiva should only be given to pregnant women if clearly needed and after a careful risk/benefit analysis has been conducted for both the mother and the foetus.
Sevelamer carbonate Zentiva se smije davati trudnicama samo ako je to prijeko potrebno i nakon pažljive analize rizika i koristi kako za majku tako i za fetus.
Sevelamer carbonate Zentiva treatment should be re-evaluated in patients who develop severe constipation or other severe gastrointestinal symptoms.
Treba ponovno procijeniti nastavak liječenja lijekom Sevelamer carbonate Zentiva u bolesnika koji razviju tešku konstipaciju ili im se jave drugi teški gastrointestinalni simptomi.
Sevelamer has no or negligible influence on the ability to drive and use machines.
Sevelamer ne utječe ili zanemarivo utječe na sposobnost upravljanja vozilima i rada sa strojevima,
Sevelamer hydrochloride, which contains the same active moiety as sevelamer carbonate, has been given to normal healthy volunteers in doses of up to 14 grams per day for eight days with no undesirable effects.
Sevelamerklorid, koji sadrži istu djelatnu tvar kao sevelamerkarbonat, se davao normalnim, zdravim dobrovoljcima u dozama do 14 grama na dan tijekom osam dana bez štetnih učinaka.
Sevelamer: Co-administration of sevelamer (2400 mg tid) did not affect the pharmacokinetics of cinacalcet.
Sevelamer: Istodobna primjena sevelamera (2400 mg tri puta dnevno) ne mijenja farmakokinetiku sinakalceta.
Sevelamer: Co-administration of sevelamer (2400 mg, three times a day) did not affect the pharmacokinetics of cinacalcet.
Sevelamer: Istodobna primjena sevelamera (2400 mg, tri puta dnevno) ne mijenja farmakokinetiku sinakalceta.
Seven days pre-treatment with rifampicin (600 mg) followed by co- administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC (effect of a combined induction and inhibition).
Prethodna terapija rifampicinom (600 mg) tijekom 7 dana, a potom dodavanje repaglinida (pojedinačne doze od 4 mg), sedmoga je dana rezultiralo 50% nižom AUC (učinak je kombinacija indukcije i inhibicije).
Seven days pre-treatment with rifampicin (600 mg), followed by co- administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC (effect of a combined induction and inhibition).
Prethodna terapija rifampicinom (600 mg) tijekom 7 dana, a potom dodavanje repaglinida (pojedinačna doza od 4 mg) sedmoga je dana rezultirala 50% nižom AUC (učinak je kombinacija indukcije i inhibicije).
Seven days pre-treatment with rifampicin (600 mg), followed by co- administration of repaglinide (a single dose of 4 mg) at day seven resulted in a 50% lower AUC (effect of a combined induction and inhibition).
Prethodna terapija rifampicinom (600 mg) tijekom 7 dana, a potom dodavanje repaglinida (pojedinačne doze od 4 mg), sedmoga je dana rezultiralo 50% nižom AUC (učinak je kombinacija indukcije i inhibicije).
Seven hundred and fifty patients were randomized 1:1 to the treatment arms; they received treatment with either sunitinib in repeated 6-week cycles, consisting of 4 weeks of 50 mg daily oral administration followed by 2 weeks of rest (schedule 4/2), or IFN-α, administered as a subcutaneous injection of 3 million units (MU) the first week, 6 MU the second week, and 9 MU the third week and thereafter, on 3 non-consecutive days each week.
U terapijske je skupine u omjeru 1:1 randomizirano 750 bolesnika; dobivali su ili sunitinib u opetovnim 6-tjednim ciklusima u kojima se 4 tjedna peroralno primjenjivala doza od 50 mg na dan, nakon čega su slijedila 2 tjedna odmora (shema 4/2), ili IFN-α u obliku supkutane injekcije u dozi od 3 milijuna jedinica (engl. million units, MU) prvi tjedan, 6 MU drugi tjedan, te 9 MU treći tjedan i dalje svaki tjedan u 3 neuzastopna dana.
Seven hundred sixty (760) patients were randomized: ADENURIC 80 mg QD (n=256), ADENURIC 120 mg QD (n=251), or allopurinol 300 mg QD (n=253).
Sedamsto šezdeset (760) bolesnika je randomizirano te su primali: ADENURIC 80 mg jednom dnevno (n = 256), ADENURIC 120 mg jednom dnevno (n = 251), ili alopurinol 300 mg jednom dnevno (n = 253).
Seven major metabolites were identified and the metabolic pathways were identified as glucuronidation at the pyridine nitrogen, pyridine–N–oxidation with and without 3’–hydroxylation on the indane ring, 3’–hydroxylation of indane, p–hydroxylation of phenylmethyl moiety, and
Otkriveno je sedam glavnih metabolita, a utvrđeni metabolički putevi su glukuronidacija na piridinskom dušiku, oksidacija piridinskog dušika s 3’–hidroksilacijom na indanskom prstenu ili bez nje, 3’-hidroksilacija indana, p–hidroksilacija fenilmetilne skupine i N–depiridometilacija s
Seven metabolites were detected in plasma (including 3 active metabolites issued form O-demethylations), with the main one accounting for 5% of parent exposure.
7 metabolita (uključujući 3 aktivna metabolita O-demetiliranog oblika), s tim da glavni metabolit čini 5% izloženosti početne tvari.
Seven of 11 (64%) subjects in Group 1 (ca A/Vietnam/1204/2004 [H5N1]) had ≥ 4-fold rises in HAI antibody titer by Day 7 following receipt of the inactivated vaccine, with a geometric mean titer (GMT) of 165 and a titer range of 20 to 1280 in responders.
Sedam od 11 (64%) ispitanika u Skupini 1 (ca A/Vietnam/1204/2004 [H5N1]) imalo je ≥ 4-struko povećanje u titru HAI antitijela do 7. dana, nakon što su primili inaktivirano cjepivo, uz vrijednost geometrijske sredine titra (engl. geometric mean titer, GMT) od 165 i raspon titra od 20 do 1280 u osoba koje su imale odgovor na cijepljenje.
Seven patients (1.6%) developed positive anti-tocilizumab antibodies; of these, six (1.4%) developed neutralizing anti-tocilizumab antibodies.
U 7 bolesnika (1,6%) razvila su se pozitivna protutijela na tocilizumab; u 6 od njih 7 (1,4%) razvila su se neutralizirajuća protutijela na tocilizumab.
Seven patients (3%) on sunitinib and none on placebo in a phase 3 GIST study experienced venous thromboembolic events; five of the seven were Grade 3 deep venous thrombosis (DVT) and two were Grade 1 or 2.
U ispitivanju GIST-a faze III venski tromboembolijski događaj imalo je sedam bolesnika (3%) liječenih sunitinibom, a niti jedan koji je dobivao placebo; pet od tih sedam bolesnika imalo je duboku vensku trombozu (DVT) stupnja 3, a dva bolesnika stupnja 1 ili 2.
Seven percent of subjects receiving the combination of Victrelis with peginterferon alfa-2b and ribavirin had neutrophil counts of < 0.5 x 109/L (Grade 4 neutropenia) compared to 4% of subjects receiving only peginterferon alfa-2b and ribavirin.
Sedam posto ispitanika koji su primali kombinaciju lijeka Victrelis s peginterferonom alfa-2b i ribavirinom imalo je < 0,5 x 109/l neutrofila (neutropeniju stupnja 4), u usporedbi s 4% ispitanika koji su primali samo peginterferon alfa-2b i ribavirin.
Seventeen (17) patients treated with ZALTRAP (1.6 %) and two (2) placebo-treated patients (0.2%) were also positive in the neutralising antibody assay.
Sedamnaest (17) bolesnika liječenih lijekom ZALTRAP (1,6%) i dva (2) bolesnika koja su primala placebo također su imali pozitivan nalaz testa na neutralizirajuća protutijela.
Seventeen (4.5%) patients on sunitinib versus 5 (1.7%) of patients on IFN-α experienced Grade 3 or greater bleeding events.
Krvarenje stupnja 3 ili većeg imalo je 17 bolesnika (4,5%) koji su dobivali sunitinib naspram 5 bolesnika (1,7%) liječenih interferonom alfa.
Seventeen percent of samples from the exterior of occlusive dressing tested positive for talimogene laherparepvec DNA but none tested positive for presence of infective virus.
Sedamnaest posto uzoraka vanjskog dijela okluzivnog zavoja bilo je pozitivno na DNK virusa talimogene laherparepvec, ali ni jedan nije bio pozitivan na prisutnost infektivnog virusa.
Seventy percent (68/97) of all enrolled subjects completed this study of which 75 % (42/56) were sustained responders.
70 % (68/97) svih uključenih ispitanika završilo je ovo ispitivanje, od kojih je 75 % (42/56) imalo trajni odgovor.
Seventy percent (68/97) of all enrolled subjects completed this study of which 75 % (42/56) were sustained responders.
70% (68/97) svih uključenih ispitanika završilo je ovo ispitivanje, od kojih je 75% (42/56) imalo trajan virološki odgovor.
Seventy percent (70%) (162/230) of genotype 1a subjects no longer had any RAVs detected at the boceprevir-resistance associated loci by population sequencing.
U 70% (162/230) ispitanika s genotipom 1a sekvenciranjem populacije nisu otkriveni RAV-ovi na lokusima povezanima s rezistencijom na boceprevir.
Seventy-five percent (21/28) of immune-active patients in the tenofovir disoproxil fumarate group had normal ALT at week 72 compared to 34% (11/32) in the placebo group.
Sedamdeset pet posto (21/28) imunološki aktivnih pacijenata u skupini liječenoj tenofovirdizoproksilfumaratom imalo je normalnu vrijednost ALT-a u 72. tjednu u usporedbi s 34% (11/32) onih u skupini liječenoj placebom.
Seventy-four percent (26/35) of patients in the tenofovir disoproxil fumarate group had normalised ALT at week 72 compared to 31% (13/42) in the placebo group.
U 74% (26/35) pacijenata u skupini liječenoj tenofovirdizoproksilfumaratom ALT se normalizirao u 72. tjednu u usporedbi s 31% (13/42) onih u skupini koja je primala placebo.
Seventy-four percent of patients had cutaneous melanoma, and 11% had mucosal melanoma; 35% of patients had PD-L1 positive melanoma (>5% tumour cell membrane expression).
Sedamdeset i četiri posto bolesnika imalo je kožni melanom, a 11% melanom sluznice; 35% bolesnika imalo je melanom pozitivan na PD-L1 (ekspresija na tumorskoj staničnoj membrani >5%).
Seventy-four percent of patients had received prior ASCT.
Sedamdeset i četiri posto (74%) bolesnika prethodno je podvrgnuto ASCT-u.
Seventy-nine (20.1%) patients were treated concomitantly with disease modifying anti − rheumatic drugs, and 37 (9.4%) patients with glucocorticoids.
79 bolesnika (20,1%) istodobno je bilo liječeno antireumatskim lijekovima koji modificiraju tijek bolesti, a 37 bolesnika (9,4%) glukokortikoidima.
Seventy-nine (20.1%) patients were treated concomitantly with disease modifying anti-rheumatic drugs, and 37 (9.4%) patients with glucocorticoids.
79 bolesnika (20,1%) istodobno je bilo liječeno antireumatskim lijekovima koji modificiraju tijek bolesti, a 37 bolesnika (9,4%) glukokortikoidima.
Seventy-one cases (in 55 patients) of bradycardia (two of which were assessed as serious, the remainder as non-serious) were reported in clinical trials.
U kliničkim ispitivanjima prijavljen je sedamdeset i jedan slučaj (u 55 bolesnika) bradikardije (od kojih su dva ocijenjena kao ozbiljna, a ostali kao ne-ozbiljni).
Seventy-one patients were randomised to receive bolus 5-FU/FA or 5-FU/FA  Avastin (5 mg/kg every 2 weeks).
Randomiziran je 71 bolesnik, ili za bolus 5-FU/FA ili za 5-FU/FA + Avastin (5 mg/kg svaka 2 tjedna).
Seventy-one percent (71%) of patients had baseline tophi.
Sedamdeset i jedan posto (71%) bolesnika imalo je tofe na početku.
Seventy-seven percent of the patients had been previously exposed to anthracyclines.
adenokarcinomom pankreasa (populacija s namjerom liječenja)
Seventy-three percent (73%) of patients enrolled into the ACTIVE-A study were unable to take VKA due to physician assessment, inability to comply with INR (international normalised ratio) monitoring, predisposition to falling or head trauma, or specific risk of bleeding; for 26% of the patients, the physician’s decision was based on the patient’s unwillingness to take VKA.
73% bolesnika uključenih u studiju ACTIVE-A nisu bili sposobni uzimati terapiju VKA prema procjeni liječnika, zbog nemogućnosti praćenja INR (International Normalised Ratio), zbog sklonosti padanju ili traumatskim ozljedama glave ili zbog specifičnog rizika od krvarenja; za 26% bolesnika odluka liječnika bila je temeljena na nevoljnosti bolesnika za uzimanje terapije VKA.
Seventy-three percent (73%) of patients enrolled into the ACTIVE-A study were unable to take VKA due to physician assessment, inability to comply with INR (international normalised ratio) monitoring, predisposition to falling or head trauma, or specific risk of bleeding; for 26% of the patients, the physician’s decision was based on the patient’s unwillingness to take VKA.
73% bolesnika uključenih u studiju ACTIVE-A nisu bili sposobni za uzimanje terapije VKA prema procjeni liječnika, zbog nemogućnosti praćenja INR (International Normalised Ratio), sklonosti padanju ili traumatskim ozljedama glave ili zbog specifičnog rizika od krvarenja; za 26% bolesnika odluka liječnika bila je temeljena na nevoljnosti bolesnika za uzimanje terapije VKA.
Seventy-three percent (73%) of patients enrolled into the ACTIVE-A study were unable to take VKA due to physician assessment, inability to comply with INR (international normalised ratio) monitoring, predisposition to falling or head trauma, or specific risk of bleeding; for 26% of the patients, the physician’s decision was based on the patient’s unwillingness to take VKA.
73% bolesnika uključenih u studiju ACTIVE-A nisu bili sposobni za uzimanje VKA terapije prema procjeni liječnika, zbog nemogućnosti praćenja INR (International Normalised Ratio), sklonosti padanju ili traumatskim ozljedama glave ili zbog specifičnog rizika od krvarenja; za 26% bolesnika odluka liječnika bila je temeljena na nevoljnosti bolesnika za uzimanje VKA terapije.
Seventy-three percent of nucleoside-experienced and 69% of nucleoside-naïve patients achieved complete response to treatment; 90% of nucleoside-experienced and 88% of nucleoside-naïve patients achieved HBV DNA suppression < 400 copies/ml.
U 73% pacijenata koji su primali nukleozide i 69% pacijenata koji prethodno nisu primali nukleozide postigao se potpuni odgovor na liječenje; u 90% pacijenata koji su primali nukleozide i 88% pacijenata koji nisu primali nukleozide postigla se supresija HBV DNK na razinu manju od 400 kopija/ml.
Several adverse events were solicited in the clinical studies and are designated with the symbol (‡).
Nekoliko je nuspojava utvrđeno u kliničkim ispitivanjima i označeno simbolom (‡).
Several cases of accidental overdose have been reported with tacrolimus; symptoms have included tremor, headache, nausea and vomiting, infections, urticaria, lethargy and increases in blood urea nitrogen, serum creatinine and alanine aminotransferase levels.
Prijavljeno je nekoliko slučajeva slučajnog predoziranja takrolimusom; simptomi su uključivali tremor, glavobolju, mučninu i povraćanje, infekcije, urtikariju, letargiju, povišenje dušika iz ureje u krvi (BUN) te kreatinina i alanin aminotransferaze u serumu.
Several cases of benign colonic polyps occurred during the course of the trials, however, the frequency was not increased compared to placebo-treated patients.
Za trajanja ispitivanja javilo se nekoliko slučajeva benignih polipa debelog crijeva, no učestalost nije bila povećana u usporedbi s bolesnicima koji su liječeni placebom.
Several cases of dexmedetomidine overdose have been reported both in the clinical trial and the post- marketing data.
U podacima iz kliničkih ispitivanja kao i onih sakupljenih nakon stavljanja ovoga lijeka na tržište zabilježeno je nekoliko slučajeva predoziranja deksmedetomidinom.
Several cases of diarrhoea were reported with a compatible timeline.
Prijavljeno je nekoliko slučajeva proljeva s kompatibilnom vremenskom povezanošću.
Several conjugated metabolites were identified, the major ones (inactive) being a glycine conjugate of the acid metabolite of O-dealkylated desaturated pitolisant and a glucuronide of a ketone metabolite of monohydroxy desaturated pitolisant.
Utvrđeno je nekoliko konjugiranih metabolita, pri čemu su glavni (neaktivni) konjugat glicina kiselinskog metabolita O-dealkiliranog nezasićenog pitolizanta i glukuronid metabolita ketona monohidroksi nezasićenog pitolizanta.
Several controlled clinical studies in which epoetins were administered to patients with a variety of common tumours including squamous head and neck cancer, lung cancer, and breast cancer, have shown an unexplained excess mortality.
Nekoliko kontroliranih kliničkih ispitivanja u kojima su primjenjivani epoetini pokazalo je neobjašnjiv povećanje smrtnosti kod bolesnika s različitim uobičajenim tumorima uključujući skvamozni tumor glave i vrata, karcinom pluća i karcinom dojke.
Several controlled clinical studies in which epoetins were administered to patients with a variety of common tumours including squamous head and neck cancer, lung cancer, and breast cancer, have shown an unexplained excess mortality.
Nekoliko kontroliranih kliničkih ispitivanja u kojima su primjenjivani epoetini pokazalo je neobjašnjivo povećanje smrtnosti kod bolesnika s različitim uobičajenim tumorima uključujući skvamozni tumor glave i vrata, karcinom pluća i karcinom dojke.
Several genotypes of hepatitis C virus exist, and the combination of medicines used and the duration of treatment will depend on the genotype of hepatitis C virus the patient is infected with and the nature of the liver problems they have, for example if they have liver cirrhosis (scarring) or their liver is not working properly.
Postoji nekoliko genotipova virusa hepatitisa C, a kombinacija korištenih lijekova i trajanje terapije ovisi o genotipu virusa hepatitisa C kojim je zaražen bolesnik i prirodi njihovih problema s jetrom (na primjer, imaju li cirozu jetre (ožiljke) ili im jetra pravilno ne radi).
Several genotypes of hepatitis C virus exist, and the combination of medicines used and the duration of treatment will depend on which genotype of hepatitis C virus the patient is infected with, and the nature of the liver problems they have (for example, if they have liver cirrhosis (scarring) or their liver is not working properly).
Postoji nekoliko genotipova virusa hepatitisa C, a kombinacija korištenih lijekova i trajanje terapije ovisi o genotipu virusa hepatitisa C kojim je zaražen bolesnik i prirodi njegovih problema s jetrom (na primjer, ima li cirozu jetre (ožiljke) ili mu jetra pravilno ne radi).
Several of the interaction studies (indicated by # in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
Nekoliko ispitivanja interakcija (označeno s # u donjoj tablici) provodilo se s nižom dozom darunavira od preporučene, ili uz različit režim doziranja (vidjeti dio 4.2 Doziranje).
Several of the interaction studies (indicated by # in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
Nekoliko ispitivanja interakcija (označeno s # u tablici ispod) provodilo se s nižom dozom darunavira od preporučene, ili uz različit režim doziranja (vidjeti dio 4.2 Doziranje).
Several other side effects are seen in more than 1 patient in 10.
Nekoliko drugih nuspojava uočeno je u više od 1 na 10 bolesnika.
Several published studies have established the usefulness of lutetium (177Lu) in radiolabelling medicines for diagnosing and treating neuroendocrine tumours.
Nekoliko objavljenih ispitivanja utvrdilo je korisnost lutecija (177Lu) u radioaktivnom označavanju lijekova za dijagnosticiranje i liječenje neuroendokrinih tumora.
Several published studies have established the usefulness of lutetium (177Lu) in radiolabelling medicines for diagnosing and treating neuroendocrine tumours.
Nekoliko objavljenih ispitivanja utvrdilo je korisnost lutecija (177Lu) u radiooznačavanju lijekova za dijagnosticiranje i liječenje neuroendokrinih tumora.
Several studies against placebo have shown that Fluenz may have some efficacy in adults.
Nekoliko ispitivanja pokazalo je da Fluenz u usporedbi s placebom može biti donekle djelotvorno kod odraslih.